Treatment of severe regurgitation of stentless aortic valve prosthesis with a self-expandable biological valve.
Percutaneous valvular replacement in aortic stenosis is an emerging alternative therapy for high-risk patients. Initial experience suggests that outcomes compare favorably with conventional valve surgery in selected patients with comorbidities such as advanced age. Although the current devices are approved for stenotic native valves, percutaneous approaches to treat degenerated aortic bioprostheses have been reported. Here we describe the case of an 85-year-old female with severe regurgitation of a stentless biological prosthesis treated using the third-generation of CoreValve Revalving System.
Ussia
Gian Paolo
GP
Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy. gpussia@hotmail.com
Barbanti
Marco
M
Tamburino
Corrado
C
D000369:Aged, 80 and over; D000800:Angioplasty, Balloon / Q000295:instrumentation / Q000379:methods*; D001022:Aortic Valve Insufficiency / Q000628:therapy*; D001705:Bioprosthesis; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D016896:Treatment Outcome